Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats relapsed or refractory multiple myeloma. Sold as Kyprolis, Kitprozy. Every FDA application for this active ingredient: 2 branded and 8 generic.
As of Nov 15, 2026, FDA lists 10 applications for Carfilzomib (sold as Kyprolis, Kitprozy), first approved Jul 20, 2012, with 9 new uses approved and 0 published complete response letters.
First approved: Jul 20, 2012
Applications: 10
New uses approved: 9
Complete response letters: 0
Medicare spending, 2025: $414M
First approved in the EU: Nov 19, 2015
First approved in Japan: Jul 4, 2016
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 47 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
KyprolisDrugs with a new dosage indicated for the treatment of relapsed or refractory multiple myeloma. · Ono Pharmaceutical Co., Ltd. · Nov 22, 2019
KyprolisDrugs with a new dosage and other characteristics indicated for the treatment of relapsed or refractory multiple myeloma. · Ono Pharmaceutical Co., Ltd. · May 18, 2017
Kyprolis, new ingredientDrugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. · Ono Pharmaceutical Co., Ltd. · Jul 4, 2016 · Review report
Clinical Trials
97 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Apotex
Eugia Pharma